Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma

NCT02399371 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02399371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02399371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2015
Completion date
March 20, 2026
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biphasic mesothelioma, epithelioid mesothelioma, peritoneal malignant mesothelioma, pleural biphasic mesothelioma, pleural epithelioid mesothelioma, pleural malignant mesothelioma, pleural sarcomatoid mesothelioma, recurrent peritoneal malignant mesothelioma, recurrent pleural malignant mesothelioma, sarcomatoid mesothelioma